Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination treatment regimen consists of **Diprospan** (a dual-action corticosteroid formulation combining quick-acting betamethasone sodium phosphate and long-acting betamethasone dipropionate) and **ropivacaine** (a long-acting local anesthetic). It is used for pre-emptive scalp infiltration to manage postoperative pain and post-craniotomy headache in patients undergoing elective craniotomy. The biological mechanism involves a synergistic approach: ropivacaine provides immediate and prolonged nerve conduction blockade at the surgical site, while the corticosteroid components of Diprospan exert anti-inflammatory effects that prevent the liberation of inflammatory mediators around the incision. This investigational protocol is being evaluated by **Beijing Tiantan Hospital** (Capital Medical University) to reduce opioid consumption and improve pain scores in both adult and pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate + betamethasone sodium phosphate + ropivacaine.